Skip to content

Investigating the efficacy of parallel disparity on ocular fatigue in young healthy adults

Investigating the efficacy of parallel disparity on ocular fatigue in young healthy adults

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-jRCTs032240121
Enrollment
12
Registered
2024-05-28
Start date
2024-05-28
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

eye fatigue Computer Vision Syndrome, Visual Display Terminal Syndrome

Interventions

arm A: 1st period:the machine that can be expected to reduce eye fatigue + near vision work 2nd period:near vision work only arm B: 1st period:near vision work only 2nd peri

Sponsors

Onda Hidetoshi
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Age: Persons who are between 18 and 30 years of age at the time of obtaining consent. 2) Visual acuity: Persons whose naked eye visual acuity is 1.0 or better in both eyes. 3) Persons who are capable of consenting, abide by the rules of compliance during participation in the research, undergo a preliminary examination as stipulated in the research protocol, and are able to report subjective symptoms and other symptoms. 4) Persons who have been judged by the doctor in charge of the research to be eligible to participate in the study during the preliminary examination as stipulated in the research protocol.

Exclusion criteria

Exclusion criteria: 1) Subjective refraction of +-0.5 D or more (evaluated by equivalent spherical power). 2) Persons with ocular diseases other than strabismus. 3) Those with a history of ophthalmic surgery. 4) Persons who are unable to adjust to the optotype at screening. 5)Persons with presbyopia, regulatory tension, regulatory spasm, techno-stress or smartphone presbyopia (resulting in techno-stress ophthalmopathy, dysregulation, regulatory spasm, etc.) in the regulatory microtremor analyzer AA2. 6)Persons who have used eye drops (including OTC) in the last 2 weeks. 7) Persons who have taken the following drugs (including OTC) that are thought to affect pupil diameter in the last month Antihistamine, antidepressant, anticholinergic, acetylcholine, fizostigmine, morphine, sleep-inducing drugs, etc. 8) Persons who have taken vitamin A-containing supplements or functional foods in the last three months. 9)Persons who have had photosensitive attacks or are sensitive to light stimuli. 10)Smokers, including e-cigarette smokers. 11) Persons with a history or current history of alcohol or drug dependence. 12) Persons who are allergic to phenylephrine, tropicamide, fluorescein sodium, or oxyprocaine used in this study, or who are unsuitable for mydriasis testing, such as shallow anterior chamber, or who meet other contraindications to the drugs. 13)Persons who are within 3 months of participating in another clinical study. 14)Persons who use contact lenses. 15) Other persons who are judged by the research physician to be ineligible for the study.

Design outcomes

Primary

MeasureTime frame
High Frequency Component total Average(HFCA) Subjective assessment of ocular fatigue

Secondary

MeasureTime frame
1.Objective Assessment 1. HFC33cm,40cm,50cm,67cm,1m,2m showing HFC at each viewing distance 2. HFCmin 3. HFCmax 4. Other refractive values 5. Adjustment range 2)Subjective Assessment 1. Central Flicker Value

Contacts

Public ContactAKIKO TOJU

Showa University

akiko.toju@med.showa-u.ac.jp+81-3-3300-5247

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026